Can a direct oral anticoagulant be used in a pregnant patient with pulmonary embolism?

Direct Oral Anticoagulants Should NOT Be Used in Pregnant Patients with Pulmonary Embolism

Direct oral anticoagulants (DOACs) are contraindicated during pregnancy for pulmonary embolism treatment; low-molecular-weight heparin (LMWH) is the recommended anticoagulant throughout pregnancy. 1

Recommended Treatment Approach

First-Line Therapy: LMWH

• The American Society of Hematology strongly recommends LMWH over unfractionated heparin for pregnant women with acute pulmonary embolism (strong recommendation, moderate certainty evidence). 1
• LMWH should be initiated immediately upon diagnosis and continued throughout pregnancy. 1
• Either once-daily or twice-daily dosing regimens are acceptable, though twice-daily may provide more stable anticoagulation. 1
• Routine monitoring of anti-Factor Xa levels is not recommended for most patients. 1

Why DOACs Are Contraindicated in Pregnancy

Placental Transfer and Fetal Risk

• All DOACs (rivaroxaban, apixaban, dabigatran, edoxaban) cross the placenta due to their low molecular weights (436-548 Da), confirmed in both animal studies and human placental perfusion models. 1
• This placental transfer creates risk for fetal bleeding, including potentially catastrophic intracranial hemorrhage, at any gestational age. 1
• The risk of teratogenicity is highest during organogenesis (6-10 weeks gestation) but concerns persist through 20-22 weeks as brain, genitalia, and palate development continues. 1

Limited Safety Data

• No systematic clinical data exist on pregnancy outcomes after DOAC exposure—current evidence is limited to case reports and pharmacovigilance data. 1
• A 2020 retrospective study identified 614 cases of DOAC exposure during pregnancy, with major birth defects potentially related to DOAC exposure occurring in 4% (95% CI 2-6%) of cases with known outcomes. 2
• The German Embryotox Centre reported one major cardiac malformation among 23 live births after rivaroxaban exposure, though the limited cohort size cannot rule out increased malformation risk. 1

Management of Inadvertent DOAC Exposure

If Pregnancy Occurs While on DOAC

• Discontinue the DOAC immediately and commence LMWH without delay. 1
• Inadvertent DOAC exposure alone is not considered medical grounds for pregnancy termination. 1
• Arrange early obstetric review with fetal monitoring, including early ultrasound to assess viability and screen for structural abnormalities. 1
• Provide counseling about potential risks while emphasizing that available data do not suggest high embryopathy risk. 1, 2

Special Considerations for PE Management in Pregnancy

Thrombolytic Therapy

• For hemodynamically stable pregnant patients with PE and right ventricular dysfunction, avoid adding systemic thrombolysis to anticoagulation. 1
• For life-threatening hemodynamic instability, systemic thrombolytic therapy should be administered in addition to anticoagulation despite very low certainty evidence. 1

Delivery Planning

• For patients receiving therapeutic-dose LMWH, scheduled delivery with prior discontinuation of anticoagulation is recommended to minimize bleeding risk. 1
• Low-risk acute VTE can be managed with initial outpatient therapy rather than hospital admission. 1

Common Pitfalls to Avoid

• Never prescribe DOACs to women of childbearing potential without documented counseling about pregnancy avoidance and adequate contraception. 1
• Do not delay switching from DOAC to LMWH if pregnancy is discovered—every day of exposure matters during organogenesis. 1
• Avoid warfarin during pregnancy as well, particularly during the first trimester when it carries well-established teratogenic risks. 1
• Do not assume DOACs are safe in breastfeeding—while UFH, LMWH, and warfarin are safe options for breastfeeding women requiring anticoagulation, DOACs lack sufficient safety data. 1